Sanofi and Regeneron expanded their immunology alliance around four long-acting antibodies spanning IL-13, IL-4×IL-13, IL-4 and IL-4Rα. Sanofi will pay Regeneron $1 billion upfront; up to $7 billion more is contingent on development, regulatory…
The FDA approved Regeneron’s Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). The fully human Activin A-neutralizing antibody is the second approved medicine for…
Regeneron has entered into a ‘most favored nation’ (MFN) drug-pricing agreement with the White House, aligning certain drug prices with Medicaid benchmarks. The move reflects increasing policy pressure on pharmaceutical pricing rather than a…
Regeneron has received FDA approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy for genetic hearing loss caused by biallelic OTOF variants, marking a major milestone in sensory-organ gene therapy.
